Table 1.
Cohort | Immediate prior therapy | Study treatment |
---|---|---|
A (n = 112) | CDK4/6 inhibitor and an aromatase inhibitor | Alpelisib 300mg once daily plus fulvestrant 500 mg |
B (n = 112) | CDK4/6 inhibitor and fulvestrant | Alpelisib 300mg once daily plus letrozole 2.5 mg |
C (n = 112) | Chemotherapy or endocrine therapy | Alpelisib 300mg once daily plus fulvestrant 500 mg |